Nuclear medicine industry expert Buurlage joins SHINE
SHINE Medical Technologies LLC today announced the appointment of Harrie Buurlage as vice president, European operations. Mr. Buurlage will oversee all of SHINE’s activities in Europe, including the company’s siting, construction and operation of a medical isotope production facility there.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190904005577/en/
Harrie Buurlage, SHINE’s vice president, European operations (Photo: Business Wire)
Mr. Buurlage brings more than 25 years of experience in the nuclear medicine industry to his new role at SHINE, including positions in management, operations, and sales and marketing.
Mr. Buurlage was chief operating officer and then managing director of NRG, an international nuclear service provider, in the Netherlands. Among other things, Mr. Buurlage oversaw the operation of all of NRG’s nuclear installations, including the Dutch High Flux medical isotope production facility in Petten, which produces isotopes used in more than 30,000 patient treatments a day. He led a multi-year transition of the company from a science institute to a more robust health care organization.
Before joining NRG, Mr. Buurlage was global director of manufacturing for Covidien USA, now Curium Pharma, where he was responsible for radiopharmaceutical isotope manufacturing and distribution at facilities in the Netherlands, United Kingdom and United States. Mr. Buurlage oversaw the addition of a new reactor to Covidien’s supply chain in only nine months. He also drove logistical improvements in Europe, the Middle East and Africa, and was global chairman of the company’s nuclear medicine council.
Earlier in this career, Mr. Buurlage spent nearly 15 years at Mallinckrodt, where he served in positions of increasing responsibility at Petten, including managing director of Mallinckrodt Medical (MM) B.V. and director of EMEA operations.
“It is well known that current European producers of medical isotopes are planning to cease operations in the next several years, and SHINE is excited to be in a position to ensure that Europeans have uninterrupted access to the life-saving products our team and technology can provide,” said Greg Piefer, founder and CEO of SHINE. “Harrie’s experience in the nuclear industry and European market, and his management, operations and logistics expertise will be invaluable to SHINE as we execute our plan there. We look forward to working with Harrie to make a SHINE European presence a reality, and provide for a robust European and global supply chain.”
Mr. Buurlage studied applied physics at the University of Groningen. He earned certification as a radiation safety officer at the University of Leiden, the highest-level certification of its kind in Europe, which allows holders to supervise large, complex nuclear sites.
“The company’s accelerator technology, talented team and vision for Europe, the United States and the rest of the world are incredibly compelling,” Mr. Buurlage said. “I know the European market well and am confident that SHINE will play a significant role here and in the global market, particularly because of its safer, cleaner and more cost-effective production process.”
About Medical Isotopes
Medical isotopes are radioisotopes that are used in the diagnosis and treatment of disease. Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium 99m (Tc-99m). The workhorse of nuclear medicine, Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and to stage cases of cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce a variety of medical isotopes, including Mo‑99. Roughly one percent of all Mo-99 in the world decays every hour, meaning it must be produced continuously. Current production is limited to only a handful of government-owned nuclear research reactors, the majority of which are overseas.
About SHINE Medical Technologies LLC
Founded in 2010, SHINE is a development-stage company working to become a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies. It does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for Mo-99. In 2014, SHINE announced the execution of Mo-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated that SHINE Mo-99 can act as a drop-in replacement for reactor-based Mo-99. In 2016, SHINE received regulatory approval from the Nuclear Regulatory Commission to construct its production facility. The company began construction of the facility in the spring of 2019. Learn more at https://shinemed.com.
Director, Marketing & Corporate Communications
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verimatrix and Qt Company Join Forces at Embedded World 2020 to Showcase IoT Shielding21.2.2020 19:35:00 EET | Press release
Verimatrix, (Paris:VMX), formerly known as Inside Secure, a global provider of innovative, customer-friendly cybersecurity solutions that protect video content, endpoint devices, software and applications, today announced its 2nd annual collaboration at Embedded World with The Qt Company (Nasdaq Helsinki: QTCOM), a global software company with the leading independent technology behind millions of devices and applications. Verimatrix will showcase a pre-integrated solution of the Verimatrix Code Protection product with the Qt Software Framework at the Qt Ecosystem stand at Embedded World 2020 in Nuremberg, Germany. Qt is the platform of choice for in-vehicle systems, medical devices, industrial automation devices, and other business critical application manufacturers. Verimatrix Software Shielding suite consists of Code Protection, Whitebox and ProtectMyApp tools; with Code Protection and Whitebox now integrated within the Qt software development framework – the industry’s first-ever su
Counterpoint Research: Fugro, PTC and Mapbox Lead the Spatial Intelligence Platform Capabilities21.2.2020 17:00:00 EET | Press release
With the expansion of connectivity, several innovative technologies are becoming more prevalent; location intelligence is one; leveraging location and positioning data to generate insights and create value. However, location intelligence and navigation have historically lacked the ability to navigate effectively inside buildings. This has given rise to a technology innovation that we term “Spatial Intelligence.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200221005009/en/ Counterpoint CORE Scorecard - Spatial Intelligence Platforms - (Dec-2019) (Graphic: Business Wire) Spatial intelligence platforms leverage real-time simulation of 3D models to provide visualized real-time insights, which include absorbing multiple data sets, IoT integration and enabling rapid development of digital twins. The technology can collaborate with existing new technologies like smart city, digital twins, Industry 4.0, AR/VR to create multiple i
Prohibition at Any Cost? Philip Morris International Hits Back at Global Campaign of Disinformation21.2.2020 16:58:00 EET | Press release
Statement by Dr. Moira Gilchrist BSc (Hons) Pharmacy, PhD Pharmaceutical Sciences, Vice President Strategic & Scientific Communication, Philip Morris International: “‘You should develop a safer product.’ For decades, that is what governments and the public health community have told the tobacco industry. PMI has invested billions of dollars in science and technology to achieve that precise objective. “A campaign coordinated by American special interest groups, all of whom are seemingly funded by the same source—Bloomberg Philanthropies—are dedicated to just one mission. Under the guise of promoting public health, they are working to rob adults who smoke of their right to choose scientifically substantiated better alternatives to continued smoking. We have a question for them: Why are they using an elaborate network of organizations to deceive adults who smoke, elected officials, and the public health community? We can only conclude that they are pursuing a disastrous prohibition-only c
Preeminent Tax Practitioner Yash Rupal to Join Simpson Thacher in London21.2.2020 13:00:00 EET | Press release
Simpson Thacher & Bartlett LLP announced today that Yash Rupal will join the Firm as a Partner in its London office where he will be a part of its global Tax Practice. He currently heads the London Tax Group at Linklaters. Yash represents a broad range of U.K. and international corporate clients, financial institutions, investment funds, hedge funds, asset managers and their respective executives on complicated, often cross-border, mergers and acquisitions, investment fund planning and tax planning matters. He also advises extensively on tax disputes, tax litigation and HMRC enquiries. “We are delighted to welcome Yash to Simpson Thacher,” said Bill Dougherty, Chairman of the Firm’s Executive Committee. “With more than 30 years of experience advising many of the world’s leading asset managers and financial institutions, Yash is widely regarded as one of the most preeminent tax practitioners in London. He will expand our tax capabilities for clients with interests in the U.K., continent
Tej Kohli Foundation Seeks to Incubate New Projects That Can Eliminate Corneal Blindness By 203521.2.2020 11:00:00 EET | Press release
The Tej Kohli Foundation is to establish a new incubator to provide seed and acceleration funding to projects with the potential to help eliminate corneal blindness worldwide. Funding, practical resources and intellectual capital will be available to both commercial and non-commercial projects that have a clear path to the prevention, treatment and cure of corneal blindness; with funding decisions based on the magnitude of the total impact that a project will likely have in poor and underserved communities worldwide by 2035, as well as the likelihood that a project will succeed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200221005010/en/ Mrs. Gurujalli Tejavathi outside her home in the Bhadradri District in India. Mrs. Tejavathi receives free eye care for a previously transplanted cornea from the Tej Kohli Foundation. (Photo: Business Wire) The Tej Kohli Foundation continues to build its position as a multi-disciplinary
Advanced Bionics Announces Voluntary Field Corrective Action of The HiRes Ultra / Ultra 3D Cochlear Implant21.2.2020 05:23:00 EET | Press release
Advanced Bionics (AB), a global leader in developing advanced cochlear implant systems, announced today that it has begun notifying regulatory authorities that it will voluntarily initiate a field corrective action related to the initial version of HiRes Ultra and Ultra 3D cochlear implant devices due to a decrease in performance experienced by a small percentage of recipients. AB’s priority is to ensure that all cochlear implant recipients and health care providers have the information they need to understand this situation and that they receive the necessary support. Existing recipients of HiRes Ultra and Ultra 3D may continue to use their device as normal. If recipients experience issues of hearing degradation they should visit their audiologist or other health care provider. In addition, we will begin the notification process for device recipients worldwide, where allowed, to make them aware of the potential issue. This voluntary action is being taken in an abundance of caution in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom